Other antiviral compounds
| Zeile 1: | Zeile 1: | ||
| + | {{ttp|p=32297571|t=2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus|pdf=|usr=}} | ||
| + | {{tp|p=32248766|t=2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19 |pdf=|usr=}} | ||
| + | |||
| + | |||
| + | |||
| + | |||
'''Arbidol''' retarget influenza | '''Arbidol''' retarget influenza | ||
{{tp|p=32373347|t=2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro |pdf=|usr=}} | {{tp|p=32373347|t=2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro |pdf=|usr=}} | ||
| Zeile 16: | Zeile 22: | ||
'''Favipiravir''' | '''Favipiravir''' | ||
{{tp|p=32346491|t=ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study |pdf=|usr=}} | {{tp|p=32346491|t=ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study |pdf=|usr=}} | ||
| + | {{tp|p=32246834|t=2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection |pdf=|usr=}} | ||
| + | {{tp|p=32350860|t=2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2 |pdf=|usr=}} | ||
'''Anti HCV nucleotides''' | '''Anti HCV nucleotides''' | ||
| Zeile 34: | Zeile 42: | ||
'''NHC''' | '''NHC''' | ||
{{tp|p=32253226|t=ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}} | {{tp|p=32253226|t=ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}} | ||
| + | |||
| + | '''Ribavirin''' | ||
| + | |||
| + | {{tp|p=32227493|t=ä. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID?19 |pdf=|usr=}} | ||
Version vom 18. Juni 2020, 12:57 Uhr
| 32297571 2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus |
32248766 2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19
Arbidol retarget influenza
32373347 2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
32360231 ä. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?
32171872 ä. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
Niclosamide
32125140 ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
32361588 2020. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19
Umifenovir
32344167 ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study
Favipiravir
32346491 ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
32246834 2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
32350860 2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2
Anti HCV nucleotides
32119961 2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Ritonavir
32344308 2020. Suggesting Ritonavir against COVID-19/SARS-CoV-2
Didanosine
32291351 2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data
Tilorone
32215760 2020. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond
Darunavir
32325127 2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients
NHC
32253226 ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
Ribavirin
32227493 ä. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID?19
